LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The LeMaitre's corporate health partly depends on how much its sales reps can do to overcome current blocks, and how soon the pandemic ends.

Checking LeMaitre Vascular For Blocked Arteries

LeMaitre has posted a strong quarter compounded by successful acquisition activity YTD, with little OPEX tied into profits in Q3. Management has widened the capital structure to be more debt inclusive, having realised the upside on Artegraft and CardioCel asset returns.

LeMaitre: Widened Capital Structure, Acquisitions Drive Top-Line Growth

Ituran Location & Control

Logitech

Shutterstock

Winnebago

Here are five top-ranked liquid stocks, Winnebago Industries, (WGO), Shutterstock (SSTK), Logitech (LOGI), Ituran Location and Control (ITRN), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.

5 Top-Ranked Liquid Stocks To Bet On For Alluring Returns

Here are four top-ranked liquid stocks, Winnebago Industries (WGO), Shutterstock (SSTK), Logitech (LOGI), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.

4 Promising Top-Ranked Liquid Stocks to Boost Your Portfolio

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)

Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen U.S. Small Company Growth Composite Portfolio returned 4.57% gross of fees, while the Russell 2000 Growth Index was up 7.17%. You should check out Polen Capital's top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Should You Be Tempted To ‘Sell' LeMaitre Vascular (LMAT) Stock

BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020, at 12:25 PM ET.

LeMaitre Vascular to Present at the Jefferies Virtual London Healthcare Conference

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q3 2020 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 76.19% and 13.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q3 Earnings and Revenues Top Estimates

Shares of LeMaitre Vascular (NASDAQ:LMAT) moved higher by 7.5% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 48.00% year over year to $0.37, which beat the estimate of $0.19.

LeMaitre Vascular: Q3 Earnings Insights

BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2020 results and announced a $0.095/share quarterly dividend.

LeMaitre Vascular Announces Q3 2020 Financial Results

BURLINGTON, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2020 financial results on Thursday, October 29, 2020, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

LeMaitre Vascular Will Announce Third Quarter 2020 Earnings Results on October 29, 2020

Louisiana-Pacific

Smith & Wesson Brands

To increase the likelihood of unearthing high-quality companies, Benjamin Graham, the pioneer of value investing, recommended screening the market for stocks with a current ratio of more than 2 and higher working capital than long-term debt.

3 High-Quality Stock Picks

3 High Quality Stock Picks

LeMaitre Vascular is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: LeMaitre Vascular

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q2 2020 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 440.00% and 59.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Tops Q2 Earnings and Revenue Estimates

BURLINGTON, Mass., July  23, 2020  (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2020 results and announced a $0.095/share quarterly dividend.

LeMaitre Vascular Announces Q2 2020 Financial Results

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LeMaitre Vascular (LMAT) Q2 Earnings Expected to Decline

BURLINGTON, Mass., July  10, 2020  (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2020 financial results on Thursday, July 23, 2020, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

LeMaitre Vascular Will Announce Second Quarter 2020 Earnings Results on July 23, 2020

BURLINGTON, Mass., June  22, 2020  (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that it has acquired the business and assets of Artegraft, Inc. for $90.0 million, including $72.5 million in cash paid at closing ($65.0 million to Artegraft plus $7.5 in escrow to be released December 31, 2021) as well as potential earnout payments of $17.5 million payable based upon future sales of the acquired business.  Under the terms of the deal, LeMaitre will continue to operate Artegraft’s manufacturing facility in North Brunswick, NJ for at least three and a half years and will retain most of Artegraft’s employees, including seven sales & marketing personnel.

LeMaitre Vascular Acquires Artegraft

Medtronic

Fresenius Medical Care

MSA Safety

MSA Safety, Fresnius Medical Care, and LeMaitre Vascular are well-priced stocks on the rise with solid dividends.

3 Medical-Supply Stocks You Should Own Besides Medtronic

MacroGenics

QuidelOrtho Corp

Zynex Inc

An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.

Trump Pushes for US-Made Medical Products: 4 Winners

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q1 2020 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -2.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

News for LeMaitre Vascular Stock (LMAT)